Recordati Industria Chimica e Farmaceutica SPA Statistics
Recordati Industria Chimica e Farmaceutica SPA (0KBS) Stock Statistics & Valuation Metrics
Total Valuation
Recordati Industria Chimica e Farmaceutica SPA has a market cap or net worth of EUR 10.89B. The enterprise value is EUR 12.70B.
- Market Cap
- EUR 10.89B
- Enterprise Value
- EUR 12.70B
Share Statistics
Recordati Industria Chimica e Farmaceutica SPA has 209,125,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 209,125,150
- Owned by Insiders
- 0.08%
- Owned by Institutions
- 8.62%
Financial Efficiency
Recordati Industria Chimica e Farmaceutica SPA’s return on equity (ROE) is 0.23 and return on invested capital (ROIC) is 12.11%.
- Return on Equity (ROE)
- 0.23
- Return on Assets (ROA)
- 0.08
- Return on Invested Capital (ROIC)
- 12.11%
- Return on Capital Employed (ROCE)
- 0.17
- Revenue Per Employee
- 557.93K
- Profits Per Employee
- 94.53K
- Employee Count
- 4,693
- Asset Turnover
- 0.50
- Inventory Turnover
- 1.54
Valuation Ratios
The current PE Ratio of Recordati Industria Chimica e Farmaceutica SPA is 20.69. Recordati Industria Chimica e Farmaceutica SPA’s PEG ratio is 0.70.
- PE Ratio
- 20.69
- PS Ratio
- 3.94
- PB Ratio
- 4.71
- Price to FCF
- 18.00
- Price to Operating Cash Flow
- 16.68
- PEG Ratio
- 0.70
Income Statement
In the last 12 months, Recordati Industria Chimica e Farmaceutica SPA had revenue of 2.62B and earned 443.62M in profits. Earnings per share was 2.16.
- Revenue
- 2.62B
- Gross Profit
- 1.79B
- Operating Income
- 719.74M
- Pretax Income
- 581.27M
- Net Income
- 443.62M
- EBITDA
- 887.00M
- Earnings Per Share (EPS)
- 2.16
Cash Flow
In the last 12 months, operating cash flow was 660.61M and capital expenditures -55.93M, giving a free cash flow of 604.68M billion.
- Operating Cash Flow
- 660.61M
- Free Cash Flow
- 604.68M
- Free Cash Flow per Share
- 2.90
Dividends & Yields
Recordati Industria Chimica e Farmaceutica SPA pays an annual dividend of ―, resulting in a dividend yield of 2.54%
- Dividend Per Share
- ―
- Dividend Yield
- 2.54%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 5.55%
- Earnings Yield
- 4.76%
Stock Price Statistics
- Beta
- 0.67
- 52-Week Price Change
- 1.93%
- 50-Day Moving Average
- 52.84
- 200-Day Moving Average
- 50.61
- Relative Strength Index (RSI)
- 48.90
- Average Volume (3m)
- 90.53K
Important Dates
Recordati Industria Chimica e Farmaceutica SPA upcoming earnings date is Feb 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Feb 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Recordati Industria Chimica e Farmaceutica SPA as a current ratio of 1.59, with Debt / Equity ratio of 128.53%
- Current Ratio
- 1.59
- Quick Ratio
- 1.08
- Debt to Market Cap
- 0.24
- Net Debt to EBITDA
- 2.30
- Interest Coverage Ratio
- 7.25
Taxes
In the past 12 months, Recordati Industria Chimica e Farmaceutica SPA has paid 137.65M in taxes.
- Income Tax
- 137.65M
- Effective Tax Rate
- 0.24
Enterprise Valuation
Recordati Industria Chimica e Farmaceutica SPA EV to EBITDA ratio is 12.36, with an EV/FCF ratio of 20.82.
- EV to Sales
- 4.55
- EV to EBITDA
- 12.36
- EV to Free Cash Flow
- 20.82
- EV to Operating Cash Flow
- 19.06
Balance Sheet
Recordati Industria Chimica e Farmaceutica SPA has EUR 503.26M in cash and marketable securities with EUR 2.21B in debt, giving a net cash position of -EUR 1.70B billion.
- Cash & Marketable Securities
- EUR 503.26M
- Total Debt
- EUR 2.21B
- Net Cash
- -EUR 1.70B
- Net Cash Per Share
- -EUR 8.15
- Tangible Book Value Per Share
- -EUR 3.90
Margins
Gross margin is 71.38%, with operating margin of 31.11%, and net profit margin of 18.96%.
- Gross Margin
- 71.38%
- Operating Margin
- 31.11%
- Pretax Margin
- 24.94%
- Net Profit Margin
- 18.96%
- EBITDA Margin
- 36.82%
- EBIT Margin
- 28.89%
Analyst Forecast
The average price target for Recordati Industria Chimica e Farmaceutica SPA is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 8.27%
- EPS Growth Forecast
- 30.25%

